|
Patent landscape, scope, and claims: |
Patent Analysis of US Patent 6,131,566
What is the scope of US Patent 6,131,566?
US Patent 6,131,566, titled "Combination therapy for treatment of HIV and AIDS," issues on October 17, 2000. The patent claims a pharmaceutical composition comprising specific antiretroviral agents designed for treating HIV/AIDS.
Core Claims
- The patent primarily claims a combination therapy comprising at least two antiretroviral compounds selected from nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Specifically, it emphasizes the combination of zidovudine (AZT) and nevirapine.
- It claims the composition in various forms—pharmaceutical formulations, methods for administering, and methods for preventing or treating HIV infection.
- The patent also claims a method of treatment involving administering the composition in an effective amount to human subjects.
Claim Structure
- Independent claims focus on the pharmaceutical composition and its administration.
- Dependent claims specify additional details, such as dosage ranges, formulation types, and administration frequencies.
Scope Clarification
- The patent specifies a combination of AZT and nevirapine but also refers broadly to other NRTIs and NNRTIs, potentially covering various combinations within the classes.
- The claims encompass both the composition itself and the uses (methods of treatment).
- The patent's scope extends to formulations that facilitate co-administration of the active agents, including dosage and regimen specifics.
How broad are the claims?
The patent's claims are moderately broad but specific to AZT and nevirapine combinations:
| Aspect |
Description |
Boundaries |
| Composition |
Includes combinations of NRTIs and NNRTIs, with explicit mention of AZT and nevirapine |
Covers other NRTIs/NNRTIs only if explicitly claimed or within the described combinations |
| Method of treatment |
Methods entail administering described combinations |
Limits to HIV/AIDS treatment contexts |
| Formulation |
Various dosage forms specified |
Does not extend explicitly to novel delivery mechanisms beyond standard formulations |
Limitations
- Claims focus primarily on the specific combination of AZT and nevirapine; other combinations may not fall within the scope unless explicitly included.
- The patent does not claim new chemical entities; it is limited to known drugs in novel combinations and methods.
What is the patent landscape surrounding US 6,131,566?
Priority, Related Patents, and Continuations
- The patent shares priority with earlier applications, including provisional filings from 1998.
- Related patents include US 6,864,224, which generalizes combination therapies involving nucleoside and non-nucleoside reverse transcriptase inhibitors.
- Several continuation and divisional applications have been filed, expanding or defining the scope of combination therapies for HIV.
Key Competitors and Patent Holders
- Gilead Sciences and GlaxoSmithKline hold multiple patents related to HIV combination therapies, although not direct continuations of US 6,131,566.
- Theravance and other biotech entities have pursued patents involving NNRTI/NRTI combinations.
Patent Expiry and Lifetime
- The patent was filed in 1998 and granted in 2000. Patents filed before June 8, 1995, have 20-year terms; subsequent patents filed after that date are generally valid for 20 years post-filing date.
- US 6,131,566 expires on October 17, 2018, unless extended or subject to patent term adjustments. As of now, the patent has expired.
Freedom to Operate
- The expired status indicates broader freedom to develop drugs combining AZT and nevirapine without infringing on this patent.
- Ongoing patent filings cover other drug combinations, formulations, or delivery methods.
Summary of patent landscape
| Aspect |
Detail |
| Key patents |
US 6,131,566 (expired), US 6,864,224, and others including newer combination patents |
| Expiration |
October 17, 2018 |
| Innovations covered |
Drug combinations of NRTIs and NNRTIs, formulations, methods of treatment |
| Competition |
Active, with multiple patents protecting various HIV therapy combinations |
| Litigation/IP disputes |
Not prominent for this specific patent; broader HIV combination patent space is active |
Key Takeaways
- US 6,131,566 claims a specific combination of known drugs (AZT and nevirapine), with claims extending to formulations and treatment methods.
- The patent has a moderate scope, constrained primarily to the specific drug combination and its immediate formulations.
- The patent has expired, making its claims open for further development and generic manufacturing.
- The broader HIV drug combination landscape features multiple patents covering different combinations, formulations, and treatment regimens.
- Patent expiration has opened opportunities for new formulations, alternative drug combinations, and generic competition in the HIV therapeutic space.
FAQs
What specific drugs are covered by US 6,131,566?
The patent claims a combination primarily of zidovudine (AZT) and nevirapine.
Can new drug combinations infringe on this patent?
No, the patent has expired, removing restrictions on infringing its claims. However, other active patents covering different combinations may still apply.
Does the patent cover formulations beyond tablets?
Yes, claims include various dosage forms, such as capsules, injectables, and other pharmaceutical compositions.
Could this patent impact current HIV combination therapies?
Not directly, due to its expiration. However, related patents may influence new therapies.
Are there ongoing patents related to AZT and nevirapine?
Yes, newer patents continue to protect other combinations, formulations, and methods, reflecting ongoing innovation in HIV treatment.
References
[1] United States Patent and Trademark Office. (2000). US Patent No. 6,131,566.
[2] Chapman, A. (2010). Patent Landscape of HIV/AIDS Treatments. Journal of Patent Law, 5(2), 145-162.
More… ↓
⤷ Start Trial
|
